Standard Article

Metabolomics in Systems Toxicology: Towards Personalized Medicine

Systems Toxicology

Metabolomic Technology

  1. Laura K. Schnackenberg,
  2. Jinchun Sun,
  3. Richard D. Beger

Published Online: 15 SEP 2011

DOI: 10.1002/9780470744307.gat217

General, Applied and Systems Toxicology

General, Applied and Systems Toxicology

How to Cite

Schnackenberg, L. K., Sun, J. and Beger, R. D. 2011. Metabolomics in Systems Toxicology: Towards Personalized Medicine. General, Applied and Systems Toxicology. .

Author Information

  1. US Food and Drug Administration, Division of Systems Biology, National Center for Toxicological Research, Jefferson, AR, USA

Publication History

  1. Published Online: 15 SEP 2011

Abstract

Metabolomics along with systems biology technologies such as transcriptomics and proteomics has the capability of providing translational diagnostic, prognostic and mechanistic biomarkers of drug-induced injury. Metabolomics has several advantages over the other omics platforms, such as ease of sample preparation, data acquisition and use of biofluids collected through minimally invasive procedures in pre-clinical and clinical studies. The role of metabolomics in systems toxicology is reviewed and examples of metabolomics in pre-clinical and clinical studies are provided. The role of metabolomics in personalized medicine is provided with special sections focusing on drug–drug and drug–nutrient interactions, metabolic fluxes and challenge tests.

Keywords:

  • metabolomics;
  • metabonomics;
  • metabolic fluxes;
  • biomarkers;
  • personalized medicine;
  • systems biology